New hope for leukemia patients too sick for chemo?

NCT ID NCT04150029

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a new drug called sabatolimab combined with two other drugs (azacitidine and venetoclax) in 90 adults with acute myeloid leukemia who were not healthy enough for intensive chemotherapy. The goal was to see if the combination could help patients achieve remission. However, the study was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Sabatolimab (MBG453) plus azacitidine and venetoclax

What this could lead to

If successful, this combination could offer a new treatment option for AML patients who cannot tolerate standard chemotherapy.

What could go wrong

The trial was terminated early, so results are limited. It is a phase 2 study, and the combination may cause serious side effects or not improve outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Show contact details

Locations

25Uni of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
Chattanooga Onc And Hem Assoc PC

Chattanooga, Tennessee, 37404, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Duke Univ Medical Center

Durham, North Carolina, 27710, United States
Huntsman Cancer Institute Univ of Utah

Salt Lake City, Utah, 84112 0550, United States
Levine Cancer Insitute Carolinas Healthcare System

Charlotte, North Carolina, 28204, United States
MD Anderson Cancer Center University of Texas

Houston, Texas, 77030, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering

New York, New York, 10017, United States
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Vancouver, British Columbia, V5Z 1M9, Canada
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Montreal, Quebec, H3T 1E2, Canada
Novartis Investigative Site

Paris, 75475, France
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Leipzig, Saxony, 04103, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Milan, MI, 20162, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Fukushima, Fukushima, 960 1295, Japan
Novartis Investigative Site

Yamagata, Yamagata, 990 9585, Japan
Novartis Investigative Site

Seoul, Seocho gu, 06591, South Korea
Novartis Investigative Site

Barcelona, 08036, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Uni Of Iowa Hospitals And Clinics

Iowa City, Iowa, 52242, United States
Weill Cornell Medicine NY-Presb

New York, New York, 10021, United States
Yale University School Of Medicine

New Haven, Connecticut, 06520, United States